Introduction
flowchart TD
diagnostics_accuracy_rankings["Diagnostic Accuracy Rankings"]
style diagnostics_accuracy_rankings fill:#4fc3f7,stroke:#333,color:#000
diagnostics_accuracy_0["Alzheimers Disease Diagnostics"]
diagnostics_accuracy_rankings -->|"includes"| diagnostics_accuracy_0
style diagnostics_accuracy_0 fill:#81c784,stroke:#333,color:#000
diagnostics_accuracy_1["Biomarker Accuracy"]
diagnostics_accuracy_rankings -->|"includes"| diagnostics_accuracy_1
style diagnostics_accuracy_1 fill:#ef5350,stroke:#333,color:#000
diagnostics_accuracy_2["Blood-Based Biomarkers Emerging"]
diagnostics_accuracy_rankings -->|"includes"| diagnostics_accuracy_2
style diagnostics_accuracy_2 fill:#ffd54f,stroke:#333,color:#000
diagnostics_accuracy_3["Parkinsons Disease Diagnostics"]
diagnostics_accuracy_rankings -->|"includes"| diagnostics_accuracy_3
style diagnostics_accuracy_3 fill:#ce93d8,stroke:#333,color:#000
diagnostics_accuracy_4["Clinical Diagnostics"]
diagnostics_accuracy_rankings -->|"includes"| diagnostics_accuracy_4
style diagnostics_accuracy_4 fill:#4fc3f7,stroke:#333,color:#000
diagnostics_accuracy_5["Emerging Biomarkers"]
diagnostics_accuracy_rankings -->|"includes"| diagnostics_accuracy_5
style diagnostics_accuracy_5 fill:#81c784,stroke:#333,color:#000
This page ranks diagnostic methods and biomarkers for neurodegenerative diseases by their sensitivity, specificity, and clinical utility. [@jack2023]
Alzheimer's Disease Diagnostics
Biomarker Accuracy
...Introduction
Mermaid diagram (expand to render)
This page ranks diagnostic methods and biomarkers for neurodegenerative diseases by their sensitivity, specificity, and clinical utility. [@jack2023]
Alzheimer's Disease Diagnostics
Biomarker Accuracy
| Rank | Biomarker | Sensitivity | Specificity | Clinical Use | [@postuma2015]
|------|-----------|--------------|-------------|--------------| [@hansson2024]
| 1 | Amyloid PET (Pittsburgh) | 90% | 85% | Confirmed AD |
| 2 | CSF p-tau181 | 85% | 85% | Screening |
| 3 | CSF t-[tau](/proteins/tau) | 80% | 75% | Supportive |
| 4 | FDG-PET | 75% | 70% | Differential |
| 5 | Volumetric MRI | 70% | 65% | Staging |
Blood-Based Biomarkers (Emerging)
| Rank | Biomarker | Sensitivity | Specificity | Status |
|------|-----------|--------------|-------------|--------|
| 1 | Plasma p-tau181 | 85% | 85% | Clinical |
| 2 | Plasma [p-tau217](/biomarkers/p-tau-217) | 90% | 85% | Clinical |
| 3 | Plasma p-tau231 | 80% | 80% | Clinical |
| 4 | Plasma [GFAP](/entities/gfap) | 75% | 70% | Research |
| 5 | Plasma [NFL](/biomarkers/neurofilament-light-chain-nfl) | 70% | 65% | Research |
Parkinson's Disease Diagnostics
Clinical Diagnostics
| Rank | Method | Sensitivity | Specificity | Notes |
|------|--------|-------------|-------------|-------|
| 1 | DaTscan (DAT SPECT) | 80% | 85% | FDA approved |
| 2 | MIBG myocardial scintigraphy | 75% | 80% | Japan approved |
| 3 | Olfactory testing | 70% | 65% | Screening |
| 4 | Autonomic testing | 65% | 70% | Research |
| 5 | Sleep study (RBD) | 60% | 60% | Early marker |
Emerging Biomarkers
| Rank | Biomarker | Sensitivity | Specificity | Status |
|------|-----------|--------------|-------------|--------|
| 1 | [Alpha-synuclein](/proteins/alpha-synuclein) RT-QuIC (CSF) | 85% | 90% | Clinical |
| 2 | Alpha-synuclein Seed Amplification | 80% | 90% | Research |
| 3 | PlasmaNfL | 70% | 65% | Research |
| 4 | Skin biopsy | 75% | 80% | Clinical |
Amyotrophic Lateral Sclerosis
Diagnostic Methods
| Rank | Method | Sensitivity | Specificity | Use |
|------|--------|-------------|-------------|-----|
| 1 | EMG | 95% | 80% | Gold standard |
| 2 | Nerve conduction studies | 70% | 90% | Standard |
| 3 | MRI | 60% | 85% | Differential |
| 4 | CSF biomarkers | 65% | 70% | Research |
| 5 | Genetic testing | 70% | 100% | Confirmatory |
Frontotemporal Dementia
Diagnostic Accuracy
| Rank | Method | Sensitivity | Specificity | Notes |
|------|--------|-------------|-------------|-------|
| 1 | FDG-PET | 75% | 80% | Key tool |
| 2 | MRI (atrophy pattern) | 70% | 75% | Standard |
| 3 | CSF (progranulin) | 60% | 95% | Genetic |
| 4 | Neuropsych testing | 80% | 60% | Screening |
Dementia with Lewy Bodies (DLB) Diagnostics
Clinical Diagnostic Criteria
The 2017 DLB consensus criteria provide the framework for diagnosis[@jack2023][@postuma2015]:
| Rank | Feature | Sensitivity | Specificity | Clinical Use |
|------|---------|-------------|-------------|--------------|
| 1 | Core clinical features | Variable | Variable | Foundation |
| 2 | Suggestive features | Variable | Variable | Supportive |
| 3 | Indicative biomarkers | Variable | Variable | Confirmation |
Core Clinical Features
| Feature | Sensitivity | Specificity |
|---------|-------------|-------------|
| Visual hallucinations | 60-80% | 70-90% |
| Spontaneous parkinsonism | 50-70% | 80-90% |
| Cognitive fluctuation | 50-70% | 70-85% |
| REM sleep behavior disorder | 50-80% | 80-90% |
Diagnostic Biomarkers
| Rank | Biomarker | Sensitivity | Specificity | Status |
|------|-----------|-------------|-------------|--------|
| 1 | DaTscan (DAT SPECT) | 75-85% | 85-90% | FDA approved |
| 2 | CSF alpha-synuclein RT-QuIC | 85-95% | 80-90% | Clinical |
| 3 | Polysomnography (RBD) | 80-90% | 80-90% | Clinical |
| 4 | Olfactory testing | 60-70% | 65-75% | Screening |
| 5 | MIBG scintigraphy | 70-80% | 75-85% | Japan approved |
DaTscan (DAT SPECT) Accuracy
DaTscan is a key imaging biomarker for DLB[@hansson2024]:
- Sensitivity: 75-85% for differentiating DLB from AD
- Specificity: 85-90% for differentiating DLB from AD
- Use: Differentiating DLB from Alzheimer's disease
- Limitation: Cannot distinguish DLB from Parkinson's disease
REM Sleep Behavior Disorder (RBD)
RBD is a strong prodromal marker for DLB[@rbd]:
- Prevalence in DLB: 50-80% of DLB patients
- Sensitivity: 80-90% as prodromal marker
- Specificity: 80-90% for synucleinopathies
- Value: Early detection, can precede diagnosis by years
Olfactory Testing
Olfactory dysfunction is common in DLB:
- Sensitivity: 60-70%
- Specificity: 65-75%
- Use: Screening, early detection
- Advantage: Simple, inexpensive
CSF Alpha-Synuclein RT-QuIC
Seed amplification assays represent a breakthrough[@csf2023]:
- Sensitivity: 85-95% in DLB patients
- Specificity: 80-90% vs. non-synucleinopathies
- Advantages: High accuracy, early detection
- Limitations: Specialized laboratory required
MIBG Myocardial Scintigraphy
- Sensitivity: 70-80%
- Specificity: 75-85%
- Target: Cardiac sympathetic denervation
- Region: Approved in Japan
Differential Diagnosis
| Feature | DLB | AD | PDD |
|---------|-----|----|-----|
| Visual hallucinations early | +++ | + | ++ |
| Parkinsonism | +++ | - | +++ |
| DaTscan abnormal | +++ | - | +++ |
| RBD | +++ | - | +++ |
| Memory prominent early | + | +++ | + |
[@jack2023]: [DLB diagnostic criteria 2017](https://doi.org/10.1016/j.jalz.2017.04.012)
[@postuma2015]: [DLB clinical features](https://doi.org/10.1212/WNL.0000000000007158)
[@hansson2024]: [DaTscan in DLB diagnosis](https://doi.org/10.296/j radiology.2023.01.015)
[@rbd]: [RBD as DLB marker](https://doi.org/10.1212/WNL.0000000000012000)
[@csf2023]: [CSF RT-QuIC in DLB](https://doi.org/10.1001/jamaneurol.2023.0001)
Differential Diagnosis
AD vs. FTD vs. DLB
| Feature | AD | FTD | DLB |
|---------|----|----|-----|
| Memory early | +++ | + | ++ |
| Language early | + | +++ | + |
| Visual hallucinations | + | + | +++ |
| Parkinsonism | + | + | +++ |
| Fluctuation | - | - | +++ |
Progressive Supranuclear Palsy (PSP) Diagnostics
Biomarker Accuracy
| Rank | Biomarker | Sensitivity | Specificity | Clinical Use |
|------|-----------|--------------|-------------|--------------|
| 1 | MRI (midbrain atrophy, HCT) | 80% | 85% | Standard |
| 2 | Tau PET (Flortaucipir) | 75% | 80% | Emerging |
| 3 | CSF p-tau181 | 65% | 75% | Research |
| 4 | FDG-PET (pattern) | 70% | 75% | Differential |
| 5 | DaTscan | 50% | 60% | Limited |
MRI Biomarkers
- Midbrain atrophy: "Hummingbird sign" on sagittal MRI
- Superior cerebellar peduncle: "Morning glory sign"
- Third ventricle dilation: General atrophy marker
- Quantification: MR planimetry improves accuracy
Tau PET
- Flortaucipir (AV-1451): Binds to PSP-tau
- Limitations: Off-target binding in basal ganglia
- Clinical utility: Supports clinical diagnosis
Emerging Methods
- Skin biopsy: Detection of 4R-tau
- Blood biomarkers: Plasma p-tau181, p-tau231
- Olfactory testing: May differentiate from PD
Corticobasal Syndrome (CBS) Diagnostics
Biomarker Accuracy
| Rank | Biomarker | Sensitivity | Specificity | Clinical Use |
|------|-----------|--------------|-------------|--------------|
| 1 | MRI (asymmetric atrophy) | 75% | 70% | Standard |
| 2 | Tau PET | 65% | 75% | Emerging |
| 3 | FDG-PET (pattern) | 70% | 70% | Differential |
| 4 | CSF biomarkers | 60% | 70% | Research |
| 5 | DaTscan | 55% | 65% | Limited |
MRI Biomarkers
- Asymmetric cortical atrophy: Key diagnostic feature
- Basal ganglia: T2 hyperintensity, atrophy
- Callosal atrophy: "Parrot beak" sign
- Quantification: Asymmetry index improves specificity
Tau PET
- Flortaucipir: Shows asymmetric uptake in CBS
- Differential: Helps distinguish from AD
- Limitations: 4R-tau binding variable
Differential Diagnosis
- From AD: Asymmetry, motor features early
- From PSP: Lateralized features, apraxia
- From CBD: Overlapping features common
4R-Tauopathies Overview
Diseases
| Disease | Key Features | Tau Isoforms |
|---------|--------------|--------------|
| PSP | Vertical gaze palsy, falls | 4R |
| CBS | Asymmetric rigidity, apraxia | 4R |
| AGD | Argyrophilic grains | 4R |
| CBD | Cortical dysfunction | 4R |
Clinical Utility
Practical Considerations
| Factor | Importance |
|--------|------------|
| Accessibility | Blood > CSF > Imaging |
| Cost | Genetic < Blood < CSF < PET |
| Invasiveness | Clinical > Imaging > Blood |
| Turnaround time | Hours to weeks |
Related Pages
- [Diagnostics Index](/diagnostics)
- [Biomarker Types Overview](/diagnostics/biomarker-overview)
- [Biomarkers](/biomarkers)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
Coverage Gaps
Missing Disease-Specific Diagnostic Sections
The current Diagnostic Accuracy Rankings covers major diseases but has significant gaps:
Multiple System Atrophy (MSA) — No dedicated MSA diagnostic section:
- MRI biomarkers (hot cross bun sign, putaminal atrophy)
- MIBG scintigraphy utility
- Autonomic function testing
- Skin biopsy for alpha-synuclein
- CSF biomarkers
Dementia with Lewy Bodies (DLB) — Only mentioned in differential, needs dedicated section:
- DLB diagnostic criteria accuracy
- DaTscan sensitivity/specificity
- REM sleep behavior disorder as predictor
- Olfactory testing
- CSF alpha-synuclein
Vascular Dementia — Absent from rankings:
- MRI vascular burden scoring
- Hachinski Ischemic Score
- CSF biomarkers
- Differential from AD
Creutzfeldt-Jakob Disease (CJD) — Not covered:
- 14-3-3 protein in CSF
- Tau protein elevation
- Real-time QuIC (RT-QuIC)
- MRI diffusion-weighted imaging
Huntington's Disease — Missing diagnostics:
- Genetic testing accuracy
- MRI volumetric analysis
- CSF biomarkers (neurofilament light chain)
- Quantitative motor assessments
Underdeveloped Areas
Genetic Testing Coverage — Limited:
- [APP](/entities/app-protein), [PSEN1](/entities/psen1), [PSEN2](/entities/psen2) for FAD
- [LRRK2](/entities/lrrk2), [GBA](/entities/gba), SNCA, PINK1, PARK2 for PD
- [C9orf72](/entities/c9orf72), GRN, MAPT for FTD
- [HTT](/proteins/huntingtin) for Huntington's
Blood-Based Biomarkers — Need more comprehensive coverage:
-NfL across diseases
- GFAP for astrocyte activation
- Tau isoforms (p-tau181, p-tau217, p-tau231)
- Alpha-synuclein in blood
Digital Biomarkers — Absent:
- Smartphone-based assessments
- Wearable sensor metrics
- Voice analysis
- Gait analysis
Recommendations
Priority gaps to address:
Add MSA diagnostic rankings section
Add DLB diagnostic rankings section
Expand genetic testing coverage
Add vascular dementia diagnostics
Add CJD diagnostic accuracyReferences
[Jack CR, et al., NIA-AA Research Framework. Alzheimer's Dement. 2023 (2023)](https://doi.org/10.1016/j.jalz.2019.01.004)
[Postuma RB, et al., MDS research criteria. Mov Disord. 2015 (2015)](https://doi.org/10.1002/mds.26424)
[Hansson O, et al., Blood biomarkers. Nat Rev Neurol. 2024 (2024)](https://doi.org/10.1038/s41582-023-00789-3)
[Unknown, RBD as DLB marker (n.d.)](https://doi.org/10.1212/WNL.0000000000012000)
[Unknown, CSF RT-QuIC in DLB (2023)](https://doi.org/10.1001/jamaneurol.2023.0001)